Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia
Status:
Terminated
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess safety and amount of the study drug in the blood after
increasing doses of SP-420. The study will be conducted in patients with β-thalassemia.